ZIM Laboratories Limited (ZIMLAB.NS)
INR 112.56
(0.39%)
INR 112.56
(0.39%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.26 Billion INR | -36.56% |
| 2022 | 1.99 Billion INR | 19.57% |
| 2021 | 1.67 Billion INR | 25.84% |
| 2020 | 1.32 Billion INR | 13.92% |
| 2019 | 1.16 Billion INR | -29.88% |
| 2018 | 1.66 Billion INR | 33.24% |
| 2017 | 1.24 Billion INR | 14.17% |
| 2016 | 1.09 Billion INR | 3.2% |
| 2015 | 1.05 Billion INR | 34.0% |
| 2014 | 789.78 Million INR | 1.22% |
| 2013 | 780.23 Million INR | 13.88% |
| 2012 | 685.12 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 261.41 Million INR | -39.28% |
| 2023 Q1 | 363.28 Million INR | -34.95% |
| 2023 FY | 1.26 Billion INR | -36.56% |
| 2023 Q4 | 430.55 Million INR | -17.32% |
| 2023 Q3 | 520.76 Million INR | 13.44% |
| 2023 Q2 | 459.06 Million INR | 26.36% |
| 2022 Q1 | 470.16 Million INR | -3.84% |
| 2022 FY | 1.99 Billion INR | 19.57% |
| 2022 Q4 | 558.45 Million INR | 12.7% |
| 2022 Q3 | 495.53 Million INR | 4.82% |
| 2022 Q2 | 472.74 Million INR | 0.55% |
| 2021 FY | 1.67 Billion INR | 25.84% |
| 2021 Q2 | 418.78 Million INR | 33.68% |
| 2021 Q4 | 488.93 Million INR | 8.89% |
| 2021 Q3 | 449.02 Million INR | 7.22% |
| 2021 Q1 | 313.26 Million INR | 49.9% |
| 2020 FY | 1.32 Billion INR | 13.92% |
| 2020 Q3 | 389.65 Million INR | 1.97% |
| 2020 Q2 | 382.13 Million INR | 10.33% |
| 2020 Q1 | 346.34 Million INR | 114.58% |
| 2020 Q4 | 208.98 Million INR | -46.37% |
| 2019 Q1 | 301.57 Million INR | -19.4% |
| 2019 FY | 1.16 Billion INR | -29.88% |
| 2019 Q4 | 161.4 Million INR | -56.39% |
| 2019 Q3 | 370.13 Million INR | 11.55% |
| 2019 Q2 | 331.79 Million INR | 10.02% |
| 2018 Q4 | 374.16 Million INR | -26.46% |
| 2018 FY | 1.66 Billion INR | 33.24% |
| 2018 Q3 | 508.78 Million INR | 20.61% |
| 2018 Q2 | 421.84 Million INR | 18.31% |
| 2018 Q1 | 356.55 Million INR | 42.35% |
| 2017 Q3 | 372.67 Million INR | 12.78% |
| 2017 Q1 | 294.18 Million INR | 0.0% |
| 2017 Q2 | 330.43 Million INR | 12.32% |
| 2017 Q4 | 250.48 Million INR | -32.79% |
| 2017 FY | 1.24 Billion INR | 14.17% |
| 2016 FY | 1.09 Billion INR | 3.2% |
| 2015 FY | 1.05 Billion INR | 34.0% |
| 2014 FY | 789.78 Million INR | 1.22% |
| 2013 FY | 780.23 Million INR | 13.88% |
| 2012 FY | 685.12 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Sigachi Industries Limited | 2 Billion INR | 36.682% |
| Ind-Swift Limited | 2.17 Billion INR | 41.644% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 13.86% |
| Sakar Healthcare Limited | 699.58 Million INR | -81.224% |
| Aurobindo Pharma Limited | 109.54 Billion INR | 98.843% |
| Innova Captab Limited | 3.46 Billion INR | 63.405% |
| Divi's Laboratories Limited | 32.44 Billion INR | 96.092% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 79.626% |
| Morepen Laboratories Limited | 6.16 Billion INR | 79.423% |
| Mankind Pharma Limited | 42.19 Billion INR | 96.995% |
| Sequent Scientific Limited | 2.97 Billion INR | 57.438% |
| Wanbury Limited | 1.73 Billion INR | 26.743% |
| Laurus Labs Limited | 15.44 Billion INR | 91.793% |
| Nectar Lifesciences Limited | 4.82 Billion INR | 73.715% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 89.803% |
| Alembic Limited | 1 Billion INR | -26.768% |
| Hikal Limited | 5.95 Billion INR | 78.721% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 95.266% |
| Neuland Laboratories Limited | 8.24 Billion INR | 84.629% |
| J. B. Chemicals & Pharmaceuticals Limited | 15.25 Billion INR | 91.691% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 98.172% |
| IOL Chemicals and Pharmaceuticals Limited | 4.71 Billion INR | 73.134% |
| Themis Medicare Limited | 2.42 Billion INR | 47.611% |
| RPG Life Sciences Limited | 2.48 Billion INR | 48.94% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 98.987% |
| Lupin Limited | 125.09 Billion INR | 98.987% |
| Amrutanjan Health Care Limited | 2.09 Billion INR | 39.456% |
| Wockhardt Limited | 7.72 Billion INR | 83.578% |
| Vaishali Pharma Limited | 90.32 Million INR | -1303.644% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 78.259% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -94.274% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 93.546% |
| FDC Limited | 6.58 Billion INR | 80.75% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.225% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -104.329% |
| Eris Lifesciences Limited | 10.42 Billion INR | 87.841% |
| Venus Remedies Limited | 2.18 Billion INR | 41.912% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 65.692% |
| Par Drugs and Chemicals Limited | 529.13 Million INR | -139.601% |
| Caplin Point Laboratories Limited | 9.2 Billion INR | 86.229% |
| Shilpa Medicare Limited | 3.56 Billion INR | 64.406% |
| Albert David Limited | 1.4 Billion INR | 9.962% |
| Ajanta Pharma Limited | 21.06 Billion INR | 93.981% |
| Hester Biosciences Limited | 1.27 Billion INR | 0.458% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 69.252% |
| Solara Active Pharma Sciences Limited | -1.65 Billion INR | 176.563% |
| Gufic Biosciences Limited | 4.07 Billion INR | 68.878% |
| Windlas Biotech Limited | 1.33 Billion INR | 5.302% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 78.071% |
| Aarey Drugs & Pharmaceuticals Limited | 113.02 Million INR | -1021.671% |
| Mangalam Drugs & Organics Limited | 691.19 Million INR | -83.424% |
| Granules India Limited | 16.79 Billion INR | 92.453% |
| Aarti Drugs Limited | 8.31 Billion INR | 84.755% |
| Bal Pharma Limited | 770.19 Million INR | -64.609% |
| Alkem Laboratories Limited | 52.29 Billion INR | 97.576% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.51% |
| Lincoln Pharmaceuticals Limited | 1.88 Billion INR | 32.809% |
| Medicamen Biotech Limited | 495.49 Million INR | -155.868% |
| Unichem Laboratories Limited | 4.86 Billion INR | 73.94% |
| Bafna Pharmaceuticals Limited | 452.15 Million INR | -180.395% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.54 Million INR | -10006.122% |
| Valiant Laboratories Limited | 138.02 Million INR | -818.512% |
| Orchid Pharma Limited | 2.32 Billion INR | 45.36% |
| Medico Remedies Limited | 262.14 Million INR | -383.632% |
| Ind-Swift Laboratories Limited | 4.13 Billion INR | 69.326% |
| Ipca Laboratories Limited | 48.58 Billion INR | 97.39% |
| Brooks Laboratories Limited | 65.62 Million INR | -1832.053% |
| Syncom Formulations (India) Limited | 559.5 Million INR | -126.596% |
| Piramal Enterprises Limited | 8.04 Billion INR | 84.238% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 97.289% |
| NATCO Pharma Limited | 25.73 Billion INR | 95.074% |
| Suven Life Sciences Limited | -200.79 Million INR | 731.39% |
| Krebs Biochemicals & Industries Limited | -108.74 Million INR | 1265.837% |
| Strides Pharma Science Limited | 14.38 Billion INR | 91.188% |
| Indoco Remedies Limited | 8.04 Billion INR | 84.237% |
| Alpa Laboratories Limited | 188.89 Million INR | -571.173% |
| Lasa Supergenerics Limited | 121.02 Million INR | -947.52% |
| Sun Pharma Advanced Research Company Limited | 391.06 Million INR | -224.194% |